SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Immunotherapy Clinical Trial

Official title:

Phase II Clinical Study of Oxaliplatin Plus S-1 (SOX) Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of Locally Advanced HER2-positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05218148
• Other study ID #: NCC-008261
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: April 1, 2022
• Est. completion date: December 1, 2025

Study information

• Verified date: March 2022
• Source: Chinese Academy of Medical Sciences
• Contact: Aiping Zhou, doctor
• Phone: 86 13691161998
• Email: zhouap1825[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The SOX regimen has became the standard perioperative chemotherapy for locally advanced gastric cancer; The immune checkpoint inhibitors have become a standard treatment for advanced or metastatic gastric cancer；For HER2-positive locally advanced gastric cancer, some phase II studies have shown that chemotherapy combined with trastuzumab can further improve the pathological remission rate;This prospective phase II clinical trial was designed, using SOX combined with sintilimab and trastuzumab to treat HER2 positive locally advanced gastric or gastroesophageal junction adenocarcinoma patients.

Description:

This phase II trial is a single-arm and single-center clinical study. Neoadjuvant chemotherapy is a standard treatment for locally advanced gastric cancer. The SOX regimen has became the standard perioperative chemotherapy regimen for locally advanced gastric cancer. For HER2-positive locally advanced gastric cancer, the neoadjuvant treatment is still based on chemotherapy alone. Some phase II studies have shown that chemotherapy combined with trastuzumab can further improve the pathological response. But it has not yet become a standard treatment strategy.

In the field of gastric cancer, checkpoint inhibitors have become a standard treatment for advanced or metastatic gastric cancer. PD-1 monoclonal antibody (Sintilimab) + trastuzumab + chemotherapy (SOX regimen ) may be an ideal perioperative treatment for HER2-positive locally advanced gastric cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 44
• Est. completion date: December 1, 2025
• Est. primary completion date: October 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Sign the informed consent form.

• Locally advanced adenocarcinoma of the stomach or gastroesophageal junction (Siewert type II/III) confirmed by pathology or cytology.

• The definition of a positive HER2 test result is as follows: IHC detects HER2 3+ or IHC detects HER2 2+ and FISH is positive.

• Clinically, based on chest, abdomen and pelvic CT, gastroscopy, endoscopic ultrasonography, gastrointestinal contrast, ordinary ultrasound, or laparoscopy if possible, it is judged as T3-4a N+ or T4bN any gastric cancer or gastroesophageal junction cancer (refer to AJCC Article Version 8 in stages).

• Patients have not received chemotherapy and/or immunotherapy and/or trastuzumab treatment and/or radiotherapy in the past.

• Age 18-75 years old.

• The Eastern Cooperative Oncology Group (ECOG) performance status score was 0 or 1, and there was no deterioration within 2 weeks before the first administration of the study drug.

• Good organ function:

Blood routine: hemoglobin =90g/L, white blood cell =3.0×109/L, neutrophil =1.5×109/L, platelet =100×109/L; Renal function: creatinine=1.5×upper limit of normal (UNL) or creatinine clearance =60ml/min; Liver function: total bilirubin (TBIL)=1.5×upper limit of normal (UNL); ALT=2.5×UNL, AST=2.5×UNL.

Exclusion Criteria:

• The pathology is other types besides adenocarcinoma, such as squamous cell carcinoma, adenosquamous carcinoma, neuroendocrine carcinoma and so on.

• Have received chemotherapy and/or radiotherapy in the past.

• Have received any anti-PD-1, anti-PD-L1/L2 antibodies, anti-CTLA-4 antibodies and other immunotherapy in the past.

• Have received any anti-HER2 therapy in the past.

• Intra-abdominal dissemination or distant metastasis (M1).

• Clinically significant ascites.

• Known to have allergic reactions to oxaliplatin and any ingredients or excipients of Tiggio.

• Known to have allergic reactions to any ingredients or excipients of Sintilimab and Trastuzumab.

• Inability to swallow, intestinal obstruction, or other factors that affect the administration and absorption of the drug.

Related Conditions & MeSH terms

• Adenocarcinoma
• Gastric or Gastroesophageal Junction Adenocarcinoma
• HER2-positive
• Immunotherapy
• Locally Advanced Solid Tumor
• Oxaliplatin
• S-1
• Sintilimab

Intervention

Drug:
• sintilimab
Sintilimab 200mg was administered as a 30-60 min intravenous (IV) infusion every 3 weeks.3 cycles before surgery and 5 cycles after surgery.
• Trastuzumab
Trastuzumab was 8mg/kg for the first time, and 6mg/kg for the follow-up. 3 cycles before surgery and 5 cycles after surgery.
• S-1 plus oxaliplatin
Oxaliplatin 130 mg/m2 was administered IV every 3 weeks. S-1 was given orally twice daily for the first 2 weeks of each 3-week cycle. The S-1 dose was 40 mg for body surface area (BSA) < 1.25 m2, 50 mg for BSA 1.25 to <1.5 m2 and 60 mg for BSA =1.5 m2. Body surface area &lt;1.25m2: Tegio 40mg bid day 1 ~ 14; Body surface area 1.25 ~ &lt;1.5m2: Tegio 50mg bid day 1 ~ 14; Body surface area =1.5m2: Tegio 60mg bid day 1 ~ 14; 3 cycles before surgery and 3 cycles after surgery.

Locations

Country	Name	City	State
China	Cancer Hospital & Institute, Chinese Academy of Medical Sciences	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Aiping Zhou

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Major pathological response rate (MPR)	Proportion of subjects with residual tumor less than 10% or complete response	Up to 6 months
Secondary	Pathological response rate (refer to Becker-TRG evaluation standard)	TRG level 1-3: 1a: No tumor remains at all; 1b: Less than 10% of the tumor remains 2: 10%-50% tumor residual 3: More than 50% of the tumor remains or there is no change in the tumor	Up to 3 years
Secondary	Objective response rate (ORR)	Proportion of subjects with initial RECIST 1.1 measurable disease who have complete response (CR) or partial response (PR) according to iRECIST	Up to 3 years
Secondary	Disease-free survival (DFS)	Time from Cycle 1 Day 1 treatment administration to the first documented event of: disease progression, disease recurrence following surgery (preferably biopsy proven), or death - whichever occurs first.	Up to 3 years
Secondary	Overall survival (OS)	Time from Cycle 1 Day 1 treatment administration to death due to any cause.	Up to 3 years
Secondary	Incicende of Adverse Events (AEs)	Number of patients with AE, treatment-related AE (TRAE), immune-related AEs (irAE), AE of special interest (AESI), serious adverse event (SAE) assessed by CTCAE v5.0.	Up to3 years
Secondary	Biomarker assessment	To analyze the differences of gene and immune microenvironment biomarkers among patients with different curative effects, and further explore the relationship with the efficacy of clinical treatment.; To analyze the correlation between peripheral blood indexes and the efficacy of clinical treatment.	Up to3 years